Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy
Open Access
- 18 March 2026
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 15 (1) , 2645280
Abstract
Hepatocellular carcinoma (HCC), the dominant form of primary liver cancer, is the third cause of cancer-related death worldwide.1 Immune checkpoint inhibitors (ICI) are used for the first-line trea...Keywords
Funding Information
- Departamento de Salud, Gobierno de Navarra (045-2017)
- Gobierno de Navarra (AGATA Project (0011-1411-2020-000010))
- Instituto de Salud Carlos III (PI20/00260)
- AC Grants
- Fundación Intheos
This publication has 35 references indexed in Scilit:
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapyCancer Immunology, Immunotherapy, 2018
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinomaGut, 2018
- Tumor Mutational Burden and Response Rate to PD-1 InhibitionNew England Journal of Medicine, 2017
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyNature, 2017
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerNature, 2017
- An immunogenic personal neoantigen vaccine for patients with melanomaNature, 2017
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor RegressionsClinical Cancer Research, 2014
- HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and ImmunogenicityThe Journal of Immunology, 2013
- Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic CellsThe Journal of Immunology, 1998